Comparing SiBone (NASDAQ:SIBN) & Elekta (OTCMKTS:EKTAY)

SiBone (NASDAQ:SIBN) and Elekta (OTCMKTS:EKTAY) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Earnings & Valuation

This table compares SiBone and Elekta”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93 million	5.25	-$18.90 million	($0.34)	-69.91
Elekta	$1.78 billion	1.24	-$55.38 million	($0.12)	-50.00

SiBone has higher earnings, but lower revenue than Elekta. SiBone is trading at a lower price-to-earnings ratio than Elekta, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for SiBone and Elekta, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1	0	7	0	2.75
Elekta	0	1	0	0	2.00

SiBone presently has a consensus target price of $25.00, indicating a potential upside of 5.17%. Given SiBone’s stronger consensus rating and higher possible upside, research analysts clearly believe SiBone is more favorable than Elekta.

Risk and Volatility

SiBone has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Elekta has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.

Profitability

This table compares SiBone and Elekta’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SiBone	-6.20%	-7.62%	-5.63%
Elekta	-2.38%	13.47%	3.84%

Institutional and Insider Ownership

98.1% of SiBone shares are held by institutional investors. 4.0% of SiBone shares are held by insiders. Comparatively, 41.3% of Elekta shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Elekta beats SiBone on 8 of the 14 factors compared between the two stocks.

About SiBone

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

About Elekta

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.